Based on the Knight Therapeutics Inc. stock forecast from 1 analysts, the average analyst target price for Knight Therapeutics Inc. is CAD 7.50 over the next 12 months. Knight Therapeutics Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Knight Therapeutics Inc. is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Knight Therapeutics Inc.’s stock price was CAD 5.48. Knight Therapeutics Inc.’s stock price has changed by -0.18% over the past week, -4.20% over the past month and +3.01% over the last year.
No recent analyst target price found for Knight Therapeutics Inc.
No recent average analyst rating found for Knight Therapeutics Inc.
Company Overview Knight Therapeutics Inc.
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada. Read Less
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib f...Read More
Frequently Asked Questions About Knight Therapeutics Inc. (GUD:CA) Stock
Based on ratings from 1 analysts Knight Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on GUD:CA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for GUD:CA is CAD 7.50 over the next 12 months. The maximum analyst target price is CAD 7.5 while the minimum anlayst target price is CAD 7.5.
GUD:CA stock's Price/Earning ratio is 41.51.
Our analysis grades GUD:CA stock's Price / Earning ratio at F. This means that GUD:CA stock's Price/Earning ratio is above 47% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSX exchange.
Based on this GUD:CA may be fairly valued for its sector
The last closing price of GUD:CA's stock was CAD 5.48.
The most recent market capitalization for GUD:CA is CAD 0.58B.
Based on targets from 1 analysts, the average taret price for GUD:CA is projected at CAD 7.50 over the next 12 months.
This means that GUD:CA's stock price may go up by +36.86% over the next 12 months.
We can't find any ETFs which contains Knight Therapeutics Inc.'s stock.
As per our most recent records Knight Therapeutics Inc. has 725 Employees.
Knight Therapeutics Inc.'s registered address is 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8.
You can get more information about it from Knight Therapeutics Inc.'s website at https://www.gud-knight.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Knight Therapeutics Inc. (GUD:CA) Stock
Based on ratings from 1 analysts Knight Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on GUD:CA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for GUD:CA is CAD 7.50 over the next 12 months. The maximum analyst target price is CAD 7.5 while the minimum anlayst target price is CAD 7.5.
GUD:CA stock's Price/Earning ratio is 41.51.
Our analysis grades GUD:CA stock's Price / Earning ratio at F. This means that GUD:CA stock's Price/Earning ratio is above 47% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSX exchange.
Based on this GUD:CA may be fairly valued for its sector
The last closing price of GUD:CA's stock was CAD 5.48.
The most recent market capitalization for GUD:CA is CAD 0.58B.
Based on targets from 1 analysts, the average taret price for GUD:CA is projected at CAD 7.50 over the next 12 months.
This means that GUD:CA's stock price may go up by +36.86% over the next 12 months.
We can't find any ETFs which contains Knight Therapeutics Inc.'s stock.
As per our most recent records Knight Therapeutics Inc. has 725 Employees.
Knight Therapeutics Inc.'s registered address is 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8.
You can get more information about it from Knight Therapeutics Inc.'s website at https://www.gud-knight.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GUD:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
